Improved neurologic outcome in young adults (18-39 years) with Ronopterin infused early Significantly less aggressive critical care with maintained renal function in young adults New patent filed for efficacious treatment window Discussions with US and EU regulators to support market authorization initiated vasopharm GmbH, a privately-held biopharmaceutical company focusing on novel therapeutics to treat cerebrovascular […]